Potential acquisition Tidewater Clinical Research was acquired by Eximia Research in August 2024, signaling a strategic consolidation in women's health and ophthalmology trials in the Hampton Roads/Eastern Virginia region. This creates potential cross-sell opportunities with Eximia’s broader network and existing sponsors.

Regional focus Specialization in women's health and ophthalmology within the Hampton Roads/Eastern Virginia market suggests selling partners and trial sponsors may benefit from regional CRO collaborations and site-network expansion in this underpenetrated area.

Small team leverage With a lean staff (2–10 employees), there is an opportunity to offer scalable services such as outsourced data management, centralized monitoring, or sponsor-backed site support to augment limited internal capacity and accelerate trial timelines.

Financial profile Revenue in the mid-range $10–25 million indicates room for growth services such as expanded clinical operations, patient recruitment optimization, and technology-enabled trial solutions to improve efficiency and data quality for sponsors.

Tech and data potential Existing tech stack includes common web and engagement tools; partners could propose modernization initiatives (eConsent, eSource, analytics dashboards) to enhance data integrity, patient engagement, and remote monitoring for sponsors conducting regional trials.